stanozolol

Stanozolol is a synthetic anabolic steroid derived from dihydrotestosterone (DHT) and is classified as an androgen and anabolic steroid. It was first introduced in 1962 and has been used therapeutically to treat hereditary angioedema, a condition characterized by episodes of swelling due to C1-inhibitor deficiency. Stanozolol promotes protein synthesis, cell growth (anabolism), and the development or maintenance of masculine characteristics (androgenism). Its mechanism of action involves binding to androgen receptor as an agonist, leading to increased protein anabolism and decreased bradykinin production. The drug can be administered orally or intramuscularly. It has also been used for conditions such as aplastic anemia, suboptimal growth in children, vascular disorders, and as adjunct therapy for other medical conditions. Stanozolol was withdrawn from the U.S. market in 2010 but remains notable for its history of abuse in sports doping[1][2][3][4][5].

Brand names

Winstrol

Other names

17α-methyl-2'H-androst-2-eno[3,2-c]pyrazol-17β-ol